Ulrika Andersson

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Aulin, Julia; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2287-2295, 2020

• DOI för Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
• Ladda ner fulltext (pdf) av Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Hijazi, Ziad; Verdecchia, Paolo; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial
• Ladda ner fulltext (pdf) av Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

Christersson, Christina; Wallentin, Lars; Andersson, Ulrika; Alexander, John H et al.

Ingår i Heart, s. 235-242, 2019

• DOI för Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.
• Ladda ner fulltext (pdf) av Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i American Heart Journal, s. 169-177, 2018

• DOI för Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

Horowitz, John D.; De Caterina, Raffaele; Heresztyn, Tamila; Alexander, John H. et al.

Ingår i Journal of the American College of Cardiology, s. 721-733, 2018

• DOI för Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Aulin, Julia; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2287-2295, 2020

• DOI för Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
• Ladda ner fulltext (pdf) av Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Hijazi, Ziad; Verdecchia, Paolo; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial
• Ladda ner fulltext (pdf) av Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

Christersson, Christina; Wallentin, Lars; Andersson, Ulrika; Alexander, John H et al.

Ingår i Heart, s. 235-242, 2019

• DOI för Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.
• Ladda ner fulltext (pdf) av Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i American Heart Journal, s. 169-177, 2018

• DOI för Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

Horowitz, John D.; De Caterina, Raffaele; Heresztyn, Tamila; Alexander, John H. et al.

Ingår i Journal of the American College of Cardiology, s. 721-733, 2018

• DOI för Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Sharma, Abhinav; Hijazi, Ziad; Andersson, Ulrika; Al-Khatib, Sana M. et al.

Ingår i Circulation, s. 1666-1676, 2018

• DOI för Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Proietti, M.; Hijazi, Ziad; Andersson, Ulrika; Connolly, S. J. et al.

Ingår i Journal of Internal Medicine, s. 282-292, 2018

• DOI för Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Hijazi, Ziad; Lindahl, Bertil; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J et al.

Ingår i American Heart Journal, s. 94-103, 2017

• DOI för Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

Alexander, John H; Andersson, Ulrika; Lopes, Renato D; Hijazi, Ziad et al.

Ingår i JAMA cardiology, s. 673-681, 2016

• DOI för Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

De Caterina, Raffaele; Andersson, Ulrika; Alexander, John H.; Al-Khatib, Sana M. et al.

Ingår i American Heart Journal, s. 175-183, 2016

• DOI för History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
• Ladda ner fulltext (pdf) av History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

Hijazi, Ziad; Aulin, Julia; Andersson, Ulrika; Alexander, John H. et al.

Ingår i Heart, s. 508-517, 2016

• DOI för Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

D-dimer and factor VIIa in atrial fibrillation: prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

Siegbahn, Agneta; Oldgren, Jonas; Andersson, Ulrika; Ezekowitz, Michael D et al.

Ingår i Thrombosis and Haemostasis, s. 921-930, 2016

• DOI för D-dimer and factor VIIa in atrial fibrillation: prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

Hijazi, Ziad; Hohnloser, Stefan H; Andersson, Ulrika; Alexander, John H et al.

Ingår i JAMA cardiology, s. 451-460, 2016

• DOI för Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial

Hijazi, Ziad; Verdecchia, P.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i EUROPEAN HEART JOURNAL, s. 47-47, 2016

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Sandhu, Roopinder K.; Ezekowitz, Justin; Andersson, Ulrika; Alexander, John H. et al.

Ingår i European Heart Journal, s. 2869-2878, 2016

• DOI för The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial

Hijazi, Ziad; Hohnloser, S. H.; Andersson, Ulrika; Alexander, J. H. et al.

Ingår i European Heart Journal, s. 339-339, 2015

Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation

Alexander, J.; Andersson, Ulrika; Lopes, R. D.; Hijazi, Ziad et al.

Ingår i European Heart Journal, s. 345-345, 2015

Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Lindahl, Bertil et al.

Ingår i Clinical Chemistry, s. 368-378, 2015

• DOI för Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Aulin, Julia; Siegbahn, Agneta; Hijazi, Ziad; Ezekowitz, Michael D. et al.

Ingår i American Heart Journal, s. 1151-1160, 2015

• DOI för Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Heart, s. 1193-1200, 2014

• DOI för Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin

Hijazi, Ziad; Wallentin, Lars; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of the American College of Cardiology, s. 52-61, 2014

• DOI för High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, s. 961-970, 2014

• DOI för Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial

Åsberg, S.; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i European Heart Journal, s. 426-426, 2014

The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment

Christersson, Christina; Wallentin, Lars; Andersson, Ulrika; Hylek, E. M. et al.

Ingår i European Heart Journal, s. 866-867, 2014

D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation: observations from the ARISTOTLE trial

Christersson, Christina; Wallentin, Lars; Andersson, Ulrika; Alexander, J. H. et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 1401-1412, 2014

• DOI för D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation: observations from the ARISTOTLE trial

Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation

Aulin, Julia; Hijazi, Ziad; Andersson, Ulrika; Gersh, B. J. et al.

Ingår i European Heart Journal, s. 1115-1116, 2014

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Wallentin, Lars; Hijazi, Ziad; Andersson, Ulrika; Alexander, John H. et al.

Ingår i Circulation, s. 1847-1858, 2014

• DOI för Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Granger, Christopher B. et al.

Ingår i Circulation, s. 625-634, 2014

• DOI för High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights from the ARISTOTLE trial

Hijazi, Ziad; Wallentin, Lars; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of the American College of Cardiology, s. 2274-2284, 2013

• DOI för N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights from the ARISTOTLE trial

ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy

Horowitz, J. D.; De Caterina, R.; Heresztyn, T.; Andersson, Ulrika et al.

Ingår i European Heart Journal, s. 1040-1041, 2013

• DOI för ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy

Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Granger, Christopher B. et al.

Ingår i Circulation, 2013

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1605-1616, 2012

• DOI för Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, S. J. et al.

s. 429-429, 2016